卵巢上皮性癌患者腹腔镜手术后穿刺孔种植转移的发生率及预后因素分析
回顾性分析四川省肿瘤医院2014年5月至2023年7月收治的369例有外院腹腔镜手术史的卵巢上皮性癌患者,腹壁穿刺孔种植转移(PSM)发生率为6.5%(24/369),中位间隔25.5天。22例PSM患者二次手术联合辅助治疗后中位无进展生存8.8个月、总生存27.7个月;多因素Cox分析显示手术病理分期(HR=4.579)和病理分化程度(HR=5.307)是总生存的独立危险因素。
要点
- 腹腔镜术后腹壁PSM发生率为6.5%(24/369),中位间隔25.5天。
- 22例PSM患者中位无进展生存8.8个月,中位总生存27.7个月。
- 手术病理分期(HR=4.579)和病理分化程度(HR=5.307)是OS独立危险因素。
核心结论
- 腹腔镜手术后腹壁PSM可能对卵巢癌患者预后带来不良影响,尤其是手术病理分期较晚、病理分化程度较低患者,应引起临床重视。
研究设计与样本
- 回顾性收集2014年5月至2023年7月四川省肿瘤医院妇瘤科收治的腹腔镜手术后发生腹壁PSM的卵巢上皮性癌患者22例的临床病理及随访资料。
主要发现
- 2014年5月至2023年7月共收治369例有外院腹腔镜手术史的卵巢癌患者,其中24例(6.5%,24/369)经术后病理确诊为腹壁PSM,中位间隔25.5天(四分位距19.5,32.0天)。
- 22例PSM患者年龄(53.0±8.6)岁,中位随访37.6个月(24.7,63.4个月);Ⅰ~Ⅱ期4例、Ⅲ~Ⅳ期18例;高~中分化5例、低分化17例。
- 二次手术联合术后辅助治疗后中位无进展生存8.8个月(4.6,14.3个月),中位总生存27.7个月(15.5,38.4个月)。
- 单因素Cox分析显示手术病理分期、病理分化程度、淋巴结转移状态与OS显著相关(P均<0.05);年龄、ECOG评分、病理类型、术前CA125、术后残留灶、PARP抑制剂使用与OS无关(P均>0.05)。
- 多因素Cox分析显示手术病理分期(HR=4.579,95%CI:1.111-18.866;P=0.035)和病理分化程度(HR=5.307,95%CI:1.042-27.031;P=0.045)是OS的独立危险因素。
临床怎么用
- 原文结论认为腹壁PSM可能对卵巢癌患者预后带来不良影响,尤其手术病理分期较晚、病理分化程度较低患者,应引起临床重视。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the incidence of port-site metastasis (PSM) after laparoscopic surgery in patients with epithelial ovarian cancer and prognostic factors influencing outcomes in those with abdominal wall PSM. Methods: Clinicopathological and follow-up data of 22 ovarian epithelial cancer patients diagnosed with abdominal wall PSM after laparoscopic surgery, who were treated in the Sichuan Cancer Hospital between May 2014 and July 2023, were retrospectively collected. A retrospective analysis of PSM characteristics and prognostic factors influencing outcomes, was conducted in these patients. Results: (1) Between May 2014 and July 2023, a total of 369 ovarian cancer patients with a history of laparoscopic surgery performed at other hospitals were admitted. Among them, 24 cases (6.5%, 24/369) were diagnosed with tumor lesions at the abdominal wall port sites via postoperative pathological examination, with a median interval time of 25.5 days (interquartile range: 19.5, 32.0 days) after laparoscopic surgery. Of these, 22 cases with complete clinicopathological and follow-up data were included in this study. (2) The age of the 22 PSM patients was (53.0±8.6) years, and the median follow-up time was 37.6 months (24.7, 63.4 months). Surgical-pathological staging revealed stage Ⅰ-Ⅱ disease in 4 cases and stage Ⅲ-Ⅳ disease in 18 cases. Histopathological differentiation included 5 cases of well-to-moderately differentiated tumors and 17 cases of poorly differentiated tumors. Pathological subtypes comprised 11 cases of high-grade serous adenocarcinoma, 5 cases of low-grade serous adenocarcinoma, and 6 cases of clear cell carcinoma or cystadenocarcinoma. Lymph node status was as follows: negative for lymph node metastasis (n=16), positive (n=5), and no lymphadenectomy performed (n=1). Postoperative residual disease was categorized as no macroscopic residual disease (n=13), residual disease ≤1 cm (n=7), and residual disease >1 cm (n=2). (3) Following secondary cytoreductive surgery combined with postoperative adjuvant therapy, the median progression-free survival and overall survival (OS) time of the patients were 8.8 months (4.6, 14.3 months) and 27.7 months (15.5, 38.4 months), respectively. Univariate Cox regression analysis demonstrated that surgical-pathological stage, histopathological differentiation grade, and lymph node metastasis status were significantly associated with OS time in patients with abdominal wall PSM (all P<0.05). In contrast, age, Eastern Cooperative Oncology Group performance status score, histopathological subtype, preoperative serum cancer antigen 125 level, presence of residual lesions after surgery and poly adenosine diphosphate ribose polymerase inhibitor usage showed no significant correlation with OS time (all P>0.05). Multivariate Cox regression analysis identified surgical-pathological stage (HR=4.579,95%CI:1.111-18.866;P=0.035) and histopathological differentiation grade (HR=5.307,95%CI:1.042-27.031;P=0.045) as independent risk factors for OS time in PSM patients. Conclusion: Abdominal wall PSM following laparoscopic surgery for epithelial ovarian cancer maybe adversely affect patient prognosis, particularly in cases with advanced stage and poorly differentiated tumors, which warrants significant clinical attention. 目的: 探讨卵巢上皮性癌(卵巢癌)患者腹腔镜手术后腹壁穿刺孔种植转移(PSM)的发生状况及影响腹壁PSM患者预后的相关因素。 方法: 收集2014年5月—2023年7月四川省肿瘤医院妇瘤科收治的腹腔镜手术后发生腹壁PSM的卵巢癌患者的临床病理资料及随访资料,回顾性分析腹壁PSM的发生状况,并探讨影响腹壁PSM患者预后的相关因素。 结果: (1)2014年5月—2023年7月期间共收治369例有外院腹腔镜手术史的卵巢癌患者(同期本院收治的卵巢癌患者均行开腹手术),其中24例在腹腔镜手术后中位间隔时间25.5 d(19.5,32.0 d)发现腹壁穿刺孔处存在肿瘤病灶,且经术后病理检查确诊为PSM,腹腔镜手术后腹壁PSM的发生率为6.5%(24/369);其中22例有完整临床病理资料及随访资料的腹壁PSM患者纳入本研究,中位随访时间为37.6个月(24.7,63.4个月)。(2)22例腹壁PSM患者的年龄为(53.0±8.6)岁;手术病理分期:Ⅰ~Ⅱ期4例,Ⅲ~Ⅳ期18例;病理分化程度:高~中分化5例,低分化17例;病理类型:高级别浆液性腺癌11例,低级别浆液性腺癌5例,透明细胞癌或囊腺癌6例;淋巴结转移:无淋巴结转移16例,有淋巴结转移5例,未行淋巴结切除1例;术后残留灶:无肉眼可见残留灶13例,残留灶≤1 cm 7例,残留灶>1 cm 2例。(3)二次手术联合术后辅助治疗后患者的中位无进展生存、总生存(OS)时间分别为8.8个月(4.6,14.3个月)、27.7个月(15.5,38.4个月)。单因素Cox回归模型分析显示,手术病理分期、病理分化程度、淋巴结转移状态与腹壁PSM患者的OS时间均显著相关(P均<0.05);而年龄、美国东部肿瘤协作组体能状态评分、病理类型、术前血清癌抗原125水平、术后残留灶大小、是否使用聚二磷酸腺苷核糖聚合酶抑制剂与腹壁PSM患者的OS时间均无关(P均>0.05)。多因素Cox回归模型分析显示,手术病理分期(HR=4.579,95%CI为1.111~18.866;P=0.035)、病理分化程度(HR=5.307,95%CI为1.042~27.031;P=0.045)均是影响腹壁PSM患者OS时间的独立危险因素。 结论: 腹腔镜手术后腹壁PSM可能对卵巢癌患者预后带来不良影响,尤其是手术病理分期较晚、病理分化程度较低患者,应引起临床重视。.
引用
- Shi XW, Wang DF, Zhang GN, et al. [Analysis of the incidence and prognostic factors of port-site metastasis following laparoscopic surgery in patients with ovarian epithelial carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2025. PMID: 40419352. doi:10.3760/cma.j.cn112141-20250102-00002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。